Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death

Journal of Neurochemistry

Volumn 92, Issue 6, 2005, Pages 1340-1349

  Steinbach, Joachim P ^a,c   Wolburg, Hartwig ^b   Klumpp, Andrea ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; CD95 ligand; Cycloheximide; Epidermal growth factor receptor; Glioma; Hypoxia

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN;

ARTICLE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; ENERGY CONSUMPTION; GLIOMA CELL; GLUCOSE INTAKE; HUMAN; HUMAN CELL; HYPOXIA; MITOCHONDRION; NECROSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; SENSITIZATION;

EID: 15244358389     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02957.x     Document Type: Article

References (45)

1. Brown J. M. and Wilson W. R. (2004) Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447.
2. Collingridge D. R., Piepmeier J. M., Rockwell S. and Knisely J. P. (1999) Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother. Oncol. 53, 127-131.
3. Dong Z., Venkatachalam M. A., Wang J., Patel Y., Saikumar P., Semenza G. L., Force T. and Nishiyama J. (2001) Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J. Biol. Chem. 276, 18 702-18 709.
4. Erler J. T., Cawthorne C. J., Williams K. J., Koritzinsky M., Wouters B. G., Wilson C., Miller C., Demonacos C., Stratford I. J. and Dive C. (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and - independent mechanisms and contributes to drug resistance. Mol. Cell Biol. 24, 2875-2889.
5. Ferrara N., Hillan K. J., Gerber H. P. and Novotny W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400.
6. Glaser T., Wagenknecht B., Groscurth P., Krammer P. H. and Weller M. (1999) Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene 18, 5044-5053.
7. Glaser T., Wagenknecht B. and Weller M. (2001) Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 20, 4757-4767.
8. Goldman B. (2003) For investigational targeted drugs, combination trials pose challenges. J. Natl. Cancer Inst 95, 1744-1746.
9. Harris A. L. (2002) Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47.
10. Hochachka P. W., Buck L. T., Doll C. J. and Land S. C. (1996) Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc. Natl Acad. Sci. USA 93, 9493-9498.
11. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D. and Wiegand S. J. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
12. Javelaud D. and Besancon F. (2002) Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J. Biol. Chem. 277, 37 949-37 954.
13. Kim M., Park S. Y., Pai H. S., Kim T. H., Billiar T. R. and Seol D. W. (2004) Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res. 64, 4078-4081.
14. Kleihues P., Burger P. C., Collins V. P., Newcomb E. W., Ohgaki H. and Cavenee W. K. (2000) Glioblastoma, in Pathology and Genetics of Tumours of the Nervous System (Kleihues, P. and Cavenee, W. K., eds), 2nd edn, pp. 29-39. IARC Press, Lyon, France.
15. Kleijn M., Welsh G. I., Scheper G. C., Voorma H. O., Proud C. G. and Thomas A. A. (1998) Nerve and epidermal growth factor induce protein synthesis and eIF2B activation in PC12 cells. J. Biol. Chem. 273, 5536-5541.
16. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., Koromilas A. and Wouters B. G. (2002) Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol. Cell Biol. 22, 7405-7416.
17. Lawson B. R., Baccala R., Song J., Croft M., Kono D. H. and Theofilopoulos A. N. (2004) Deficiency of the cyclin kinase inhibitor p21 (WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J. Exp. Med. 199, 547-557.
18. Lobner D. and Choi D. W. (1996) Preincubation with protein synthesis inhibitors protects cortical neurons against oxygen-glucose deprivation-induced death. Neuroscience 72, 335-341.
19. Machein M. R., Risau W. and Plate K. H. (1999) Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum. Gene Ther. 10, 1117-1128.
20. Nam S. Y., Amoscato A. A. and Lee Y. J. (2002) Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 21, 337-346.
21. Park S. Y., Billiar T. R. and Seol D. W. (2002) Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosisinducing ligand (TRAIL). Biochem. Biophys. Res. Commun. 291, 150-153.
22. Pettersen E. O., Juul N. O. and Ronning O. W. (1986) Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res. 46, 4346-4351.
23. Rajasekhar V. K., Viale A., Socci N. D., Wiedmann M., Hu X. and Holland E. C. (2003) Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysemes. Mol. Cell. 12, 889-901.
24. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 29, 427-431.
25. Read T. A., Sorensen D. R., Mahesparan R., Enger P. O., Timpl R., Olsen B. R., Hjelstuen M. H., Haraldseth O. and Bjerkvig R. (2001) Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol. 19, 29-34.
26. Reichert M., Steinbach J. P., Supra P. and Weller M. (2002) Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. Cancer 95, 1113-1119.
27. Roth W., Fontana A., Trepel M., Reed J. C., Dichgans J. and Weller M. (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44, 55-63.
28. Schmelzle T. and Hall M. N. (2000) TOR, a central controller of cell growth. Cell 103, 253-262.
29. Schmidt E. V. (1999) The role of c-myc in cellular growth control. Oncogene 18, 2988-2996.
30. Steinbach J. P. and Weller M. (2002) Mechanisms of apoptosis in CNS tumors: application to theory. Curr. Neurol. Neurosci. Rep. 2, 246-253.
31. Steinbach J. P., Supra P., Huang H.-J. S., Cavenee W. K. and Weller M. (2002) CD95-mediated apoptosis of human malignant glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol. 12, 12-20.
32. Steinbach J. P., Wolburg H., Klumpp A., Probst H. and Weller M. (2003) Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ. 10, 823-832.
33. Steinbach J. P., Klumpp A., Wolburg H. and Weller M. (2004) Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res. 64, 1575-1578.
34. Suzuki A., Tsutomi Y., Akahane K., Araki T. and Miura M. (1998) Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17, 931-939.
35. Suzuki A., Ito T., Kawano H., Hayashida M., Hayasaki Y., Tsutomi Y., Akahane K., Nakano T., Miura M. and Shiraki K. (2000) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19, 1346-1353.
36. Teicher B. A. (1994) Hypoxia and drug resistance. Cancer Metastasis Rev. 13, 139-168.
37. Thorpe P. E. (2004) Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415-421.
38. Tohma Y., Gratas C., Van Meir E. G., Desbaillets I., Tenan M., Tachibana O., Kleihues P. and Ohgaki H. (1998) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57, 239-245.
39. Traxler P., Allegrini P. R., Brandt R. et al. (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931-4941.
40. Valk P. E., Mathis C. A., Prados M. D., Gilbert J. C. and Budinger T. F. (1992) Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole. J. Nucl. Med. 33, 2133-2137.
41. Wagenknecht B., Glaser T., Naumann U., Kugler S., Isenmann S., Bahr M., Korneluk R., Liston P. and Weller M. (1999) Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 6, 370-376.
42. Weinmann M., Marini P., Jendrossek V., Betsch A., Goecke B., Budach W. and Belka C. (2004) Influence of hypoxia on TRAIL-induced apoptosis in tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 58, 386-396.
43. Weller M., Frei K., Groscurth P., Krammer P. H., Yonekawa Y. and Fontana A. (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94, 954-964.
44. Wouters B. G., van den Beucken T., Magagnin M. G., Lambin P. and Koumenis C. (2004) Targeting hypoxia tolerance in cancer. Drug Resist. Update 7, 25-40.
45. Zagzag D., Amirnovin R., Greco M. A., Yee H., Holash J., Wiegand S. J., Zabski S., Yancopoulos G. D. and Grumet M. (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab. Invest. 80, 837-849.